Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Current and Emerging Treatment Options for Locally Advanced and Metastatic Renal Cell Carcinoma
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Current and Emerging Treatment Options for Locally Advanced and Metastatic Renal Cell Carcinoma

A series of Live Grand Rounds Programs and an On-demand CME-certified Webcourse.

Welcome to "Current and Emerging Treatment Options for Locally Advanced and Metastatic Renal Cell Carcinoma.” This CME-certified initiative is intended for community-based medical oncologists, urologists, surgical oncologists, radiation oncologists, and other health care professionals involved in the treatment and care of patients with advanced or metastatic renal cell carcinoma (RCC). A series of live CME-certified programs will be presented at selected hospitals during 2016-2017, and an online CME-certified webcourse will be available in fall 2016.

Program Description

While the 5-year survival rate for RCC has improved over time, most patients with metastatic disease have limited treatment options. Several novel systemic therapies have become available for patients with unresectable RCC, but the optimal treatment sequence remains undefined. In order to ensure appropriate treatment, the multidisciplinary oncology treatment team must coordinate the care of RCC patients to optimize selection of first-line therapy, stay up to date with emerging clinical data, and take steps for the appropriate mitigation of adverse events.

Current and Emerging Treatment Options for Locally Advanced and Metastatic Renal Cell Carcinoma will employ a case-based approach that reflects the necessary collaboration and suggest patient characteristics that allow for effective treatment sequencing in the community oncology setting.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the CME-certification of this program, please email contact@potomacme.org.

Learning Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Discuss the tailored selection of first-line treatment options for patients with locally advanced or metastatic RCC
  • Evaluate recent clinical data on emerging agents for the treatment of RCC that has progressed
  • Review emerging data from ongoing clinical studies of novel therapies for metastatic RCC
  • Empower patients to become active participants in the management of treatment-related adverse events

Live Activities Schedule

If you are interested in attending a meeting in your local area, please contact Kathy Whyte at 443-909-7901 or kwhyte@rockpointe.com for the schedule.

Calendar

Back to Top

Related Online Offerings

Back to Top
Additional CME/CE-certified Oncology Exchange programming, can be found at:
www.medscape.org/sites/advances/oncologyexchange.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the Visiting Professor Series, "Current and Emerging Treatment Options for Locally Advanced and Metastatic Renal Cell Carcinoma."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Tailored selection of first-line treatment options for patients with locally advanced or metastatic RCC
  • Recent clinical data on emerging agents for the treatment of RCC that has progressed
  • Emerging data from ongoing clinical studies of novel therapies for metastatic RCC
  • Empowering patients to become active participants in the management of treatment-related adverse events

Transcript of Speaker Orientation (Coming Soon)

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation

Audio Download

CME-certified Program Slides

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint) Coming Soon

This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PDF)

Steering Committee Biographies

Back to Top

ROBERT A. FIGLIN, MD, FACPROBERT A. FIGLIN, MD, FACP

Steven Spielberg Family Chair in Hematology/Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Robert A. Figlin, MD, FACP is the Steven Spielberg Family Chair in Hematology/Oncology, Professor of Medicine and Biomedical Sciences, Director of the Division of Hematology/Oncology, and Deputy Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles, CA. Dr. Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA.

Prior to joining Cedars-Sinai, Dr. Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, he served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr. Figlin joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was appointed Co-director of the Jonsson Comprehensive Cancer Center’s Oncology Program. He also held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center.

A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin’s research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars-Sinai’s tradition of compassionate patient care. Dr. Figlin serves as Editor for Kidney Cancer Journal and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored more than 350 peer-reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer.


BRIAN I. RINI, MD, FACPBRIAN I. RINI, MD, FACP

Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. A staff member in the Department of Hematology and Medical Oncology and Leader of the Genitourinary Oncology Program at Cleveland Clinic, Dr. Rini’s work focuses on genitourinary malignancies.

Dr. Rini completed his undergraduate work at the University of Notre Dame and earned his medical degree at the Ohio State University. Dr. Rini completed a residency in internal medicine and a fellowship in hematology/oncology at the University of Chicago Hospitals. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving back to his hometown to work at Cleveland Clinic in 2005.

Dr. Rini’s primary research has been in renal cell carcinoma (RCC), with a special focus on antiangiogenic therapy and immunotherapy. He has been involved in the initial and ongoing development of targeted agents for metastatic RCC, and was an integral investigator in the clinical development of several agents which are now FDA approved. Dr. Rini’s research has been published in peer-reviewed journals that include Journal of the National Cancer Institute, Journal of Clinical Oncology, Lancet, and JAMA.

Back to Top
    

This CME-certified activity is jointly provided by Potomac Center for Medical Education and Rockpointe Oncology.

This activity is supported through educational grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.

©2016 PCME